Sirnaomics Announces Completion of IND-Enabling Studies of Safety and Efficacy for STP125G with NHP Models, Targeting ApoC3 for Treatment of Cardiovascular Diseases
Hong Kong SAR | Germantown, MD, USA | Suzhou Biobay, China, Sirnaomics Ltd. (the Company, HKG: 2257, together with its subsidiaries, the Group or Sirnaomics), a leading biopharmaceutical company engaging…